| Filed On | Filing |
|---|---|
| 02 Nov 2026 |
8-K: Results of Operations and Financial Condition
Achieves third quarter revenue growth of 10% as reported and organic and CAG Diagnostics recurring revenue growth of 11% as reported and organic. |
| 04 Aug 2026 |
8-K: Results of Operations and Financial Condition
Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. |
| 15 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
(a)All meetings of stockholders shall be held at such place within or without the State of Delaware as may be designated from time to time by the Board of Directors or the President or, if not so designated, at the registered office of t... |
| 05 May 2026 |
8-K: Results of Operations and Financial Condition
Achieves first quarter revenue growth of 14% as reported and 11% organic, and CAG Diagnostics recurring revenue growth of 14% as reported and 11% organic. |
| 26 Mar 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Consistent with our recent discussions, this letter confirms our mutual agreement regarding the end of your employment as Executive Vice President, Global Strategy and Commercial of IDEXX Laboratories, Inc. (“IDEXX”) and your continued e... |
| 13 Feb 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 02 Feb 2026 |
8-K: Results of Operations and Financial Condition
Achieves fourth quarter revenue growth of 14% as reported and 12% organic, reflecting strong CAG Diagnostics recurring revenue, growing 12% reported and 10% organic. |
| 13 Jan 2026 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
THIS AMENDED AND RESTATED CHANGE IN CONTROL AGREEMENT is made as of January 12, 2026 (this “Agreement”), by and between IDEXX Laboratories, Inc., a Delaware corporation (the “Company”), and Michael Erickson (the “Executive”). This Agreem... |
| 13 Nov 2025 |
8-K: Entry into a Material Definitive Agreement; Creation of a Direct Financial Obligation
THIS AMENDMENT NO. 2 (this “Amendment”) is made as of November 12, 2025 by and among IDEXX Laboratories, Inc., a Delaware corporation (the “Administrative Borrower”), IDEXX Distribution, Inc., a Massachusetts corporation, IDEXX Operation... |
| 03 Nov 2025 |
8-K: Results of Operations and Financial Condition
Achieves third quarter revenue growth of 13% as reported and 12% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. |
| 07 Oct 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
WESTBROOK, Maine, October 7, 2025 – IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Karen Peacock to the Company’s Board of Directors, effective October 6, 2025. |
| 04 Aug 2025 |
8-K: Results of Operations and Financial Condition
Achieves second quarter revenue growth of 11% as reported and 9% organic, supported by CAG Diagnostics recurring revenue growth of 9% as reported and 7% organic. |
| 10 Jul 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
WESTBROOK, Maine, July 10, 2025 – IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced the election of Joseph L. (Jay) Hooley to the Company's Board of Directors, effective July 10, 2025. |
| 09 May 2025 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders
(a)All meetings of stockholders shall be held at such place within or without the State of Delaware as may be designated from time to time by the Board of Directors or the President or, if not so designated, at the registered office of t... |
| 01 May 2025 |
8-K: Results of Operations and Financial Condition
Achieves first quarter revenue growth of 4% as reported and 5% organic, supported by CAG Diagnostics recurring revenue growth of 3% as reported and 4.5% organic. |
| 14 Feb 2025 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 03 Feb 2025 |
8-K: Results of Operations and Financial Condition
Achieves fourth quarter revenue growth of 6% as reported and on an organic basis, driven by CAG Diagnostics recurring revenue growth of 6% reported and 7% organic |
| 12 Dec 2024 |
8-K: Departure/Election of Directors or Officers; Compensation
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
| 09 Dec 2024 |
8-K: Other Events
WESTBROOK, Maine, December 9, 2024—IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, today announced that the Company’s Board of Directors authorized an increase in its ongoing share repurchase progra... |
| 21 Nov 2024 |
8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure
Andrew Emerson, Senior Vice President, Corporate and CAG Finance, to Serve as IDEXX’s Next CFO |
Loading...